Karyopharm Therapeutics Inc. [KPTI] President and CEO makes an insider sale of 3,722 shares worth 6,402.


The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Karyopharm Therapeutics Inc. shares valued at $6,402 were sold by Paulson Richard A. on Aug 07. At $1.72 per share, Paulson Richard A. sold 3,722 shares. The insider’s holdings dropped to 802,018 shares worth approximately $1.11 million following the completion of this transaction.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Also, Poulton Stuart sold 2,845 shares, netting a total of over 4,836 in proceeds. Following the sale of shares at $1.70 each, the insider now holds 156,286 shares.

Before that, Paulson Richard A. had sold 3,538 shares from its account. In a trade valued at $6,085, the President and CEO traded Karyopharm Therapeutics Inc. shares for $1.72 each. Upon closing the transaction, the insider’s holdings decreased to 3,538 shares, worth approximately $1.12 million.

As published in their initiating research note from Piper Sandler on January 19, 2023, Karyopharm Therapeutics Inc. [KPTI] has been an Overweight and the price target has been revised to $8. This represents a 82.62% premium over Thursday’s closing price.

Analyzing KPTI Stock Performance

On Thursday, Karyopharm Therapeutics Inc. [NASDAQ: KPTI] plunged -4.79% to $1.39. The stock’s lowest price that day was $1.37, but it reached a high of $1.47 in the same session. During the last five days, there has been a drop of approximately -17.26%. Over the course of the year, Karyopharm Therapeutics Inc. shares have dropped approximately -59.12%. Shares of the company reached a 52-week high of $4.8700 on 04/17/23 and a 52-week low of $1.3700 on 08/24/23. A 50-day SMA is recorded $1.7223, while a 200-day SMA reached $3.0536. Nevertheless, trading volume fell to 1.52 million shares from 1.09 million shares the previous day.

Support And Resistance Levels for Karyopharm Therapeutics Inc. (KPTI)

According to the 24-hour chart, there is a support level at 1.3500, which, if violated, would cause prices to drop to 1.3100. In the upper region, resistance lies at 1.4500. The next price resistance is at 1.5100. RSI (Relative Strength Index) is 29.30 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.1786, which suggests the price will decrease in the coming days. Percent R is at 95.92%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Is Karyopharm Therapeutics Inc. subject to short interest?

Stocks of Karyopharm Therapeutics Inc. saw a sharp rise in short interest on Jul 30, 2023 jumping by 2.45 million shares to 15.0 million. Data from Yahoo Finance shows that the short interest on Jun 29, 2023 was 12.55 million shares. A jump of 16.33% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.86 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.86.

Which companies own the most shares of Karyopharm Therapeutics Inc. (KPTI)?

According to BlackRock Fund Advisors filings, the company currently owns 9,038,183 shares, which is about 7.93% of the total KPTI shares outstanding. The investor’s shares have appreciated by 2,057,417 from its previous 13-F filing of 6980766.0 shares. With the completion of the buy transaction, The Vanguard Group, Inc.’s stake is now worth $15,107,333. Avidity Partners Management LP reduced a -13.12% interest valued at $15.07 million while Palo Alto Investors LP 0 stake. In its current portfolio, ExodusPoint Capital Management LP holds 2,382,451 shares valued at $4.29 million.

In terms of Karyopharm Therapeutics Inc. share price expectations, FactSet research, analysts set an average price target of $6.50 in the next 12 months, up nearly 310.96% from the previous closing price of $1.46. Analysts anticipate Karyopharm Therapeutics Inc. stock to reach $10.00 by 2023, with the lowest price target being $4.00.


Please enter your comment!
Please enter your name here